{"url_path":"/sec/mplt/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224129-index.html","accession_number":"0001193125-26-224129","cik":"0001770069","ticker":"MPLT","issuer_name":"MapLight Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224129-index.html","primary_entity_key":"0001770069","primary_entity_name":"MapLight Therapeutics, Inc."},"word_count":50,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nRule 10b5-1 Trading Arrangements\n\nNone of our directors or executive officers adopted or terminated a \"Rule 10b5-1 trading arrangement\" or \"non-Rule-10b5-1 trading arrangement,\" as each term is defined in Item 408(a) of Regulation S-K, during the fiscal quarter ended March 31, 2026.\n\n71\n\n[Table of Contents](#toc_page)"}